| Loss of PTEN promotes resistance to T cell–mediated immunotherapy W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ... Cancer discovery 6 (2), 202-216, 2016 | 1394 | 2016 |
| Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells WW Overwijk, MR Theoret, SE Finkelstein, DR Surman, LA De Jong, ... The Journal of experimental medicine 198 (4), 569-580, 2003 | 1125 | 2003 |
| BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma DT Frederick, A Piris, AP Cogdill, ZA Cooper, C Lezcano, CR Ferrone, ... Clinical cancer research 19 (5), 1225-1231, 2013 | 993 | 2013 |
| T helper 17 cells promote cytotoxic T cell activation in tumor immunity N Martin-Orozco, P Muranski, Y Chung, XO Yang, T Yamazaki, S Lu, ... Immunity 31 (5), 787-798, 2009 | 964 | 2009 |
| CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells PA Antony, CA Piccirillo, A Akpinarli, SE Finkelstein, PJ Speiss, ... The Journal of Immunology 174 (5), 2591-2601, 2005 | 958 | 2005 |
| Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade PL Chen, W Roh, A Reuben, ZA Cooper, CN Spencer, PA Prieto, JP Miller, ... Cancer discovery 6 (8), 827-837, 2016 | 943 | 2016 |
| gp100/pmel 17 is a murine tumor rejection antigen: induction of “self”-reactive, tumoricidal T cells using high-affinity, altered peptide ligand WW Overwijk, A Tsung, KR Irvine, MR Parkhurst, TJ Goletz, K Tsung, ... The Journal of experimental medicine 188 (2), 277-286, 1998 | 595 | 1998 |
| B16 as a mouse model for human melanoma WW Overwijk, NP Restifo Current protocols in immunology 39 (1), 20.1. 1-20.1. 29, 2000 | 590 | 2000 |
| Vaccination with a recombinant vaccinia virus encoding a “self” antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4+ T … WW Overwijk, DS Lee, DR Surman, KR Irvine, CE Touloukian, CC Chan, ... Proceedings of the National Academy of Sciences 96 (6), 2982-2987, 1999 | 547 | 1999 |
| Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion Y Hailemichael, Z Dai, N Jaffarzad, Y Ye, MA Medina, XF Huang, ... Nature medicine 19 (4), 465-472, 2013 | 494 | 2013 |
| PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines W Peng, C Liu, C Xu, Y Lou, J Chen, Y Yang, H Yagita, WW Overwijk, ... Cancer research 72 (20), 5209-5218, 2012 | 492 | 2012 |
| Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells V Bronte, M Wang, WW Overwijk, DR Surman, F Pericle, SA Rosenberg, ... The Journal of Immunology 161 (10), 5313-5320, 1998 | 452 | 1998 |
| BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice C Liu, W Peng, C Xu, Y Lou, M Zhang, JA Wargo, JQ Chen, HS Li, ... Clinical cancer research 19 (2), 393-403, 2013 | 407 | 2013 |
| Plasmacytoid dendritic cells induce NK cell–dependent, tumor antigen–specific T cell cross-priming and tumor regression in mice C Liu, Y Lou, G Lizée, H Qin, S Liu, B Rabinovich, GJ Kim, YH Wang, Y Ye, ... The Journal of clinical investigation 118 (3), 1165-1175, 2008 | 402 | 2008 |
| Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine … A van Elsas, RPM Sutmuller, AA Hurwitz, J Ziskin, J Villasenor, ... The Journal of experimental medicine 194 (4), 481-490, 2001 | 384 | 2001 |
| Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy TR Hodges, M Ott, J Xiu, Z Gatalica, J Swensen, S Zhou, JT Huse, ... Neuro-oncology 19 (8), 1047-1057, 2017 | 367 | 2017 |
| Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016; 6: 202–216. doi: 10.1158/2159-8290 W Peng, JQ Chen, C Liu, S Malu, C Creasy, MT Tetzlaff, C Xu, ... CD-15-0283.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 2018 | 306 | 2018 |
| Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function Y Lee, N Martin-Orozco, P Zheng, J Li, P Zhang, H Tan, HJ Park, M Jeong, ... Cell research 27 (8), 1034-1045, 2017 | 292 | 2017 |
| The immune system in cancer metastasis: friend or foe? LME Janssen, EE Ramsay, CD Logsdon, WW Overwijk Journal for immunotherapy of cancer 5, 1-14, 2017 | 268 | 2017 |
| Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice H Qin, B Lerman, I Sakamaki, G Wei, SC Cha, SS Rao, J Qian, ... Nature medicine 20 (6), 676-681, 2014 | 253 | 2014 |
Nicholas P Restifo, MDCellular Immunotherapy Explorer在 marbletx.com 的电子邮件经过验证
